Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Kiniksa Pharmaceuticals International (KNSA) Return on Invested Capital (2021 - 2025)

Kiniksa Pharmaceuticals International's Return on Invested Capital history spans 5 years, with the latest figure at 1.37% for Q4 2025.

  • For Q4 2025, Return on Invested Capital fell 128.0% year-over-year to 1.37%; the TTM value through Dec 2025 reached 1.37%, down 128.0%, while the annual FY2025 figure was 1.5%, 141.0% down from the prior year.
  • Return on Invested Capital reached 1.37% in Q4 2025 per KNSA's latest filing, down from 0.07% in the prior quarter.
  • In the past five years, Return on Invested Capital ranged from a high of 0.1% in Q2 2023 to a low of 1.37% in Q4 2025.
  • Average Return on Invested Capital over 5 years is 0.22%, with a median of 0.07% recorded in 2024.
  • Peak YoY movement for Return on Invested Capital: surged 75bps in 2023, then crashed -128bps in 2025.
  • A 5-year view of Return on Invested Capital shows it stood at 0.64% in 2021, then surged by 103bps to 0.02% in 2022, then tumbled by -491bps to 0.08% in 2023, then decreased by -6bps to 0.09% in 2024, then crashed by -1429bps to 1.37% in 2025.
  • Per Business Quant, the three most recent readings for KNSA's Return on Invested Capital are 1.37% (Q4 2025), 0.07% (Q3 2025), and 0.01% (Q2 2025).